Trust Co. of Toledo NA OH Sells 70 Shares of Zoetis Inc. (NYSE:ZTS)

Trust Co. of Toledo NA OH lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,361 shares of the company’s stock after selling 70 shares during the period. Trust Co. of Toledo NA OH’s holdings in Zoetis were worth $224,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ZTS. Callahan Advisors LLC increased its holdings in shares of Zoetis by 90.4% in the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after purchasing an additional 6,221 shares during the period. CIBC Asset Management Inc boosted its stake in Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after buying an additional 46,050 shares during the period. Schroder Investment Management Group grew its position in Zoetis by 2.6% during the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock worth $40,036,000 after buying an additional 6,169 shares in the last quarter. Vanguard Group Inc. increased its stake in Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock worth $6,739,905,000 after acquiring an additional 120,158 shares during the last quarter. Finally, Portside Wealth Group LLC increased its stake in Zoetis by 24.7% in the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company’s stock worth $5,550,000 after acquiring an additional 6,672 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ZTS shares. Piper Sandler boosted their price objective on Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Monday, May 12th. UBS Group dropped their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, May 7th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Finally, Stifel Nicolaus lowered their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $212.75.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 652 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president now owns 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.18% of the company’s stock.

Zoetis Trading Down 2.7%

ZTS stock opened at $164.27 on Monday. The company has a market capitalization of $73.13 billion, a PE ratio of 30.03, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company’s 50 day moving average price is $158.67 and its two-hundred day moving average price is $163.83.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm’s revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.38 EPS. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be given a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.22%. Zoetis’s payout ratio is 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.